Predictive Oncology (POAI) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 08, 2023
Document Information [Line Items]
Entity Central Index Key	0001446159
Entity Registrant Name	Predictive Oncology Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-36790
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-1007393
Entity Address, Address Line One	2915 Commers Drive, Suite 900
Entity Address, City or Town	Eagan
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55121
City Area Code	651
Local Phone Number	389-4800
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	POAI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,005,230

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and Cash Equivalents	$ 18,597,119	$ 22,071,523
Accounts Receivable	282,763	331,196
Inventories	380,292	430,493
Prepaid Expense and Other Assets	520,005	526,801
Total Current Assets	19,780,179	23,360,013
Property and Equipment, net	1,771,737	1,833,255
Intangibles, net	272,969	253,865
Lease Right-of-Use Assets	3,062,598	211,893
Other Long-Term Assets	174,096	75,618
Total Assets	25,061,579	25,734,644
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable	1,424,484	943,452
Accrued Expenses and Other Liabilities	1,406,069	2,229,075
Derivative Liability	12,880	13,833
Contract Liabilities	639,238	602,073
Lease Liability	427,678	94,237
Total Current Liabilities	3,910,349	3,882,670
Lease Liability – Net of current portion	2,596,845	86,082
Total Liabilities	6,507,194	3,968,752
Commitments and Contingencies
Stockholders’ Equity:
Common Stock, $.01 par value, 200,000,000 shares authorized, 3,969,993 and 3,938,160 shares outstanding as of March 31, 2023 and December 31, 2022, respectively	39,700	39,382
Additional Paid-in Capital	175,712,817	175,503,634
Accumulated Deficit	(157,199,718)	(153,777,916)
Total Stockholders’ Equity	18,554,385	21,765,892
Total Liabilities and Stockholders’ Equity	25,061,579	25,734,644
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	792	792
Series F Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	$ 794	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares outstanding (in shares)	3,969,993	3,938,160
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	2,300,000	2,300,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series F Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	80,000	0
Preferred stock, shares outstanding (in shares)	79,404	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Revenue		$ 239,895	$ 314,568
Cost of goods sold		120,139	109,443
Gross margin		119,756	205,125
General and administrative expense		2,335,984	2,423,651
Operations expense		878,518	891,071
Sales and marketing expense		370,237	304,467
Total operating loss		(3,464,983)	(3,414,064)
Other income		42,228	42,430
Other expense		0	(989)
Gain on derivative instruments		953	1,908
Net loss		$ (3,421,802)	$ (3,370,715)
Net loss per common share - basic and diluted (in dollars per share)		$ (0.86)	$ (1.02)
Weighted average shares used in computation - basic and diluted (in shares)	[1]	3,968,099	3,291,722
[1]The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Three Months Ended March 31, 2023 2022 Options 47,805 51,529 Restricted Stock Units 2,500 22,084 Warrants 1,812,379 1,583,063 Series B Convertible Preferred Stock 16 16

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series F Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2021	79,246	0	3,280,750
Balance at Dec. 31, 2021	$ 792	$ 0	$ 32,808	$ 168,272,366	$ (128,040,282)	$ 40,265,684
Shares issued to consultant and other	0	0	$ 86	162,036	0	162,122
Shares issued to consultant and other (in shares)			8,595
Vesting expense	$ 0	$ 0	$ 0	36,518	0	36,518
Net loss			$ 0	0	(3,370,715)	(3,370,715)
Balance (in shares) at Mar. 31, 2022	79,246	0	3,295,345
Balance at Mar. 31, 2022	$ 792	$ 0	$ 32,954	168,557,745	(131,410,997)	37,180,494
Shares issued pursuant to equity line		$ 0		86,825	0	86,885
Shares issued pursuant to equity line (in shares)			6,000
Balance (in shares) at Dec. 31, 2022	79,246	0	3,938,160
Balance at Dec. 31, 2022	$ 792	$ 0	$ 39,382	175,503,634	(153,777,916)	21,765,892
Shares issued to consultant and other	0	0	$ 318	200,690	0	201,008
Shares issued to consultant and other (in shares)			31,833
Vesting expense	$ 0	$ 0	$ 0	9,287	0	9,287
Series F preferred stock dividend (in shares)	0	79,404	0
Series F preferred stock dividend	$ 0	$ 794	$ 0	(794)	0	0
Net loss			$ 0	0	(3,421,802)	(3,421,802)
Balance (in shares) at Mar. 31, 2023	79,246	79,404	3,969,993
Balance at Mar. 31, 2023	$ 792	$ 794	$ 39,700	$ 175,712,817	$ (157,199,718)	$ 18,554,385

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flow from operating activities:
Net loss	$ (3,421,802)	$ (3,370,715)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	237,854	323,602
Vesting expense	9,287	36,518
Common stock issued for consulting and other	11,112	162,122
Gain on valuation of equity-linked instruments and derivative liability	(953)	(1,908)
Loss on property and equipment disposal	903	1,200
Changes in assets and liabilities:
Accounts receivable	48,433	89,230
Inventories	50,201	(67,996)
Prepaid expense and other assets	(91,682)	197,123
Accounts payable	331,332	85,037
Accrued expenses	(639,611)	(581,267)
Contract liabilities	37,165	(4,325)
Other long-term liabilities	0	37,683
Net cash used in operating activities:	(3,427,761)	(3,093,696)
Cash flow from investing activities:
Purchase of property and equipment	(24,369)	(45,399)
Acquisition of intangibles	(22,274)	(34,844)
Net cash used in investing activities:	(46,643)	(80,243)
Cash flow from financing activities:
Proceeds from issuance of common stock pursuant to equity line	0	86,885
Net cash provided by financing activities	0	86,885
Net increase (decrease) in cash and cash equivalents	(3,474,404)	(3,087,054)
Cash and cash equivalents at beginning of period	22,071,523	28,202,615
Cash and cash equivalents at end of period	18,597,119	25,115,561
Supplemental disclosure for cash flow information:
Cash payments for interest	0	989
Non-cash transactions:
Right-of-use assets obtained in exchange for lease liabilities	2,922,365	0
Series F Preferred Stock dividend	794	0
Common stock issued to settle accrued board of directors’ compensation	189,896	0
Purchase of property & equipment accrued in accounts payable	146,205	0
Acquisition of intangible assets accrued in accounts payable	$ 3,495	$ 0

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations and Continuance of Operations Predictive Oncology Inc. (“Predictive Oncology”) is a knowledge-driven company focused on applying artificial intelligence (“AI”) to support the development of optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success. The company offers a suite of solutions for oncology drug development from early discovery to clinical trials. The Company operates in three 3D The Company has determined that it will focus its resources on applying AI to support the development of optimal cancer therapies, partnering with biopharma clients to help prioritize drugs for development and identify biomarker-informed indications. Its platform provides a more informed decision tool to select optimal drug/tumor combinations to increase the probability of success during drug development. As a result of this focused approach, the Company has consolidated its brand under the Predictive Oncology name. Going forward, the Company will operate under the Predictive Oncology tradename with laboratory operations in Pittsburgh, Pennsylvania and Birmingham, Alabama. As of January 1, 2023, The Company has three 3D Note 9 Segments. The Company had cash and cash equivalents of $18,597,119 as of March 31, 2023. March 31, 2023, twelve may Recent Developments On April 19, 2023, one twenty April 24, 2023. Impact of the Coronavirus Disease 2019 In response Coronavirus Disease 2019 19” 19. 19, may 19 may 19, may 19 10 March 21, 2023. Interim Financial Statements The Company has prepared the condensed consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim condensed consolidated financial statements. Accordingly, they do not 10 March 21, 2023. may not Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates. Reclassifications Certain reclassifications have been made to the prior year’s condensed consolidated financial statements to conform to the current year presentation. The reclassifications had no Cash and cash equivalents The Company considers all highly liquid instruments with maturities when purchased of three Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the status of individual accounts. Amounts recorded in accounts receivable on the condensed consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance is maintained to provide for the estimated amount of receivables that will not 30 30 not March 31, 2023 December 31, 2022. Fair Value Measurements As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 6 Derivatives Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers, software, and office equipment 3 - 10 Leasehold improvements (1) 2 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3 ( 1 Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term. Upon retirement or sale of property and equipment, the cost and related accumulated depreciation or amortization are removed from the condensed consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred. Long-lived Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying condensed consolidated balance sheets. The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment may not may not not Goodwill In accordance with ASC 350, Intangibles Goodwill and Other not December 31, may not To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first not may first 2017 04, Simplifying the Test for Goodwill Impairment 3 1 Note 4 Intangible Assets Leases At inception of a contract, a determination is made whether an arrangement meets the definition of a lease. A contract contains a lease if there is an identified asset, and the Company has the right to control the asset. Operating leases are recorded as right-of-use (“ROU”) assets with corresponding current and noncurrent operating lease liabilities on our condensed consolidated balance sheets. Financing leases are included within fixed assets with corresponding current within other current liabilities and noncurrent within other long-term liabilities on our condensed consolidated balance sheets. ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 not The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms. Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping, and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Eagan reportable segment. Revenue from Clinical Testing Clinic diagnostic testing is comprised of our Tumor Drug Response Testing (“ChemoFx”) and Genomic Profiling (“BioSpeciFx”) tests. The Tumor Drug Response Testing test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression and/or status of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Pittsburgh’s payments terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a patient, it will account for the change as an increase to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts, as defined in ASC 606, Revenue from Contracts with Customers 30 Contract Research Organization ( CRO ) and AI-Driven Business Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. Accounts receivable totaled $282,763 and $331,196 as of March 31, 2023 December 31, 2022, The Company’s contract liabilities related primarily to 3D March 31, 2023 December 31, 2022, Practical Expedients The Company has elected the practical expedient not Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term. The fair value of each option grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: For the three months ended March 31, 2023 2022 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 90.8% 86.5% Risk-free interest rate 3.38% - 3.55% 1.83% - 1.92% Expected life (years) 10 10 On January 1, 2023, 815 40 35 815” 815 first 815, not Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $38,805 and $68,219 for the three March 31, 2023 2022, Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes 740” 740, There is no income tax provision in the accompanying condensed consolidated statements of net loss due to the cumulative operating losses that indicate a 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not Under Internal Revenue Code Section 382, may not not 382 may Tax years subsequent to 2002 Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one March 31, 2023, Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no Recently Adopted Accounting Standards In June 2016, 2016 13, not 2016 13 January 1, 2023; not In August 2020, 2020 06, 2020 06” 2020 06 may 12b 2 1934 , 2020 06 December 15, 2023, 2020 06 January 1, 2023 not

Note 2 - Inventories

Note 2 - Inventories	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 2 INVENTORIES Inventory balances are as follows: As of March 31, 2023 As of December 31, 2022 Finished goods $ 275,654 $ 290,616 Raw materials 97,944 133,183 Work-In-Process 6,694 6,694 Total $ 380,292 $ 430,493

Note 3 - Property and Equipment

Note 3 - Property and Equipment	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 3 PROPERTY AND EQUIPMENT The Company’s property and equipment consist of the following: As of March 31, 2023 As of December 31, 2022 Computers, software, and office equipment $ 485,837 $ 463,292 Leasehold improvements 669,067 535,527 Laboratory equipment 3,559,362 3,559,362 Manufacturing tooling 133,285 121,120 Demo equipment 31,555 31,554 Total 4,879,106 4,710,855 Less: Accumulated depreciation (3,107,369 ) (2,877,600 ) Total Property and Equipment, Net $ 1,771,737 $ 1,833,255 Depreciation expense, recorded within general and administrative expenses, was $231,189 and $220,078 during the three March 31, 2023 2022,

Note 4 - Intangible Assets

Note 4 - Intangible Assets	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 4 INTANGIBLE ASSETS The components of intangible assets were as follows: As of March 31, 2023 As of December 31, 2022 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Impairment Net Carrying Amount Patents & Trademarks $ 534,847 $ (261,878 ) $ 272,969 $ 509,141 $ (255,276 ) $ - $ 253,865 Developed Technology - - - 3,500,000 (386,459 ) (3,113,541 ) - Customer Relationships - - - 200,000 (22,083 ) (177,917 ) - Tradename - - - 80,000 (22,083 ) (57,917 ) - $ 534,847 $ (261,878 ) $ 272,969 $ 4,289,141 $ (685,901 ) $ (3,349,375 ) $ 253,865 Amortization expense, recorded within general and administrative expenses, was $6,665 and $103,524 during the three March 31, 2023 2022, The following table outlines the estimated future amortization expense related to intangible assets held as of March 31, 2023: Year ending December 31, Expense Remainder of 2023 $ 20,057 2024 26,743 2025 26,743 2026 26,743 2027 26,743 Thereafter 145,940 Total $ 272,969 The Company concluded there was no impairment of its finite-lived assets as of March 31, 2023.

Note 5 - Stockholders' Equity,

Note 5 - Stockholders' Equity, Stock Options and Warrants	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Equity [Text Block]	NOTE 5 STOCKHOLDERS EQUITY, STOCK OPTIONS AND WARRANTS Series F Preferred Stock Dividend and Reverse Stock Split On March 16, 2023, On March 16, 2023, one one March 27, 2023 Note 10 Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors, and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2021 53,144 $ 96.60 1,584,995 $ 33.20 Issued 1,599 8.40 1,053,136 14.00 Forfeited (2,013 ) 17.60 - - Expired (3,677 ) 208.40 (5,422 ) 329.60 Cancelled - - (816,272 ) 30.20 Outstanding at December 31, 2022 49,053 $ 91.69 1,816,437 $ 22.60 Issued 488 6.70 - - Forfeited - - - - Expired (1,736 ) 148.58 (4,058 ) 200.00 Outstanding at March 31, 2023 47,805 $ 84.88 1,812,379 $ 22.20 Stock-based compensation expense recognized for three March 31, 2023 March 31, 2022 10 March 31, 2023,

Note 6 - Derivatives

Note 6 - Derivatives	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 6 DERIVATIVES Certain warrants issued to placement agents were determined to be a derivative liability due to certain features of the warrants which could, in certain circumstances, result in the holder receiving the Black Scholes value of the outstanding warrants in the same type of consideration as the common stockholders. As a result, in those circumstances, the amount of consideration would differ from that provided to holders of common stock, therefore, the warrants were classified as a liability. The fair value of the placement agent warrants issued in connection with the March 2020 March 31, 2023 December 31, 2022, three March 31, 2023 March 31, 2022, March 2025. The fair value of the placement agent warrants issued in connection with the May 2020 March 31, 2023 December 31, 2022, three March 31, 2023 March 31, 2022, May 2025. The placement agent warrants issued in connection with the June 2020 March 31, 2023 December 31, 2022, three March 31, 2023 March 31, 2022, June 2025. The table below discloses changes in value of the Company’s embedded derivative liabilities discussed above. Derivative liability balance at December 31, 2021 $ 129,480 Gain recognized to revalue derivative instrument at fair value (1,908 ) Derivative liability balance at March 31, 2022 $ 127,572 Derivative liability balance at December 31, 2022 $ 13,833 Gain recognized to revalue derivative instrument at fair value (953 ) Derivative liability balance at March 31, 2023 $ 12,880

Note 7 - Loss Per Share

Note 7 - Loss Per Share	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 7 LOSS PER SHARE The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended 2023 2022 Numerator: Net loss attributable to common stockholders: basic and diluted calculation $ (3,421,802 ) $ (3,370,715 ) Denominator: Weighted average common shares outstanding-basic 3,968,099 3,291,722 Effect of diluted stock options, warrants, and preferred stock (1) - - Weighted average common shares outstanding - diluted 3,968,099 3,291,722 Loss per common share-basic and diluted $ (0.86 ) $ (1.02 ) ( 1 The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Three Months Ended March 31, 2023 2022 Options 47,805 51,529 Restricted Stock Units 2,500 22,084 Warrants 1,812,379 1,583,063 Series B Convertible Preferred Stock 16 16 There were 79,246 shares of Series B Convertible Preferred Stock outstanding as of March 31, 2023 March 31, 2022. March 31, 2023 March 31, 2022

Note 8 - Leases

Note 8 - Leases	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 8 LEASES The Company’s corporate offices are located in Eagan, Minnesota. The Company leases 5,773 square feet at this location, of which 2,945 square feet is used for office space and 2,828 is used for manufacturing. The lease is month-to-month tenancy. The offices of our Helomics subsidiary are located in Pittsburgh, Pennsylvania. Upon expiration of previous leases for office space and laboratory operations, the Company entered two January 4, 2023 five February 28, 2028 The Company has additional office and warehouse space located in Birmingham, Alabama. The Company leases approximately 5,274 square feet at this location. The lease is effective through August 25, 2025. Lease expense, recorded within general and administrative expenses, was $214,015 and $179,788 for the three March 31, 2023 March 31, 2022, The following table summarizes other information related to the Company’s operating leases: March 31, 2023 Weighted average remaining lease term – operating leases in years 4.76 Weighted average discount rate – operating leases 12 % The Company’s operating lease obligations as of March 31, 2023 Remainder of 2023 $ 566,485 2024 844,933 2025 839,665 2026 803,724 2027 827,909 Thereafter 139,022 Total lease payments 4,021,738 Less: interest (997,215 ) Present value of lease liabilities $ 3,024,523

Note 9 - Segments

Note 9 - Segments	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 9 SEGMENTS The Company has determined that it will focus its resources on applying AI to support the development of optimal cancer therapies, partnering with biopharma clients to help prioritize drugs for development and identify biomarker-informed indications. Its platform provides a more informed decision tool to select optimal drug/tumor combinations to increase the probability of success during drug development. As a result of this focused approach, the Company has consolidated its brand under the Predictive Oncology name. Going forward, the Company will operate under the Predictive Oncology tradename with laboratory operations in Pittsburgh, Pennsylvania and Birmingham, Alabama. As of January 1, 2023, The Company has three 3D The Company has determined its operating segments in accordance with ASC 280 Segment Reporting See discussion of revenue recognition in Note 1 Summary of Significant Accounting Policies three March 31, 2023 2022 2022 Revenue Three Months Ended March 31, 2023 2022 Pittsburgh $ 10,627 $ 21,980 Eagan 215,619 279,270 Birmingham 13,649 12,916 Corporate - 402 Total $ 239,895 $ 314,568 Segment Gain (Loss Three Months Ended March 31, 2023 2022 Pittsburgh $ (1,159,105 ) $ (1,314,513 ) Eagan (285,397 ) (48,602 ) Birmingham (482,696 ) (402,828 ) Corporate (1,494,604 ) (1,604,772 ) Total $ (3,421,802 ) $ (3,370,715 ) Assets As of As of March 31, December 31, 2023 2022 Pittsburgh $ 3,746,088 $ 1,055,228 Eagan 1,125,840 946,394 Birmingham 1,441,002 1,353,434 Corporate 18,748,649 22,379,588 Total $ 25,061,579 $ 25,734,644

Note 10 - Subsequent Events

Note 10 - Subsequent Events	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 10 SUBSEQUENT EVENTS Reverse Stock Split On April 19, 2023, one April 24, 2023. No 2012 may Redemption of Series F Preferred Stock On April 17, 2023, April 19, 2023 ( 1 1 not not March 31, 2023, April 19, 2023. NASDAQ Notice of Compliance On May 8, 2023, 10 April 24, 2023 May 5, 2023, 5550 2

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Nature of Operations Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Predictive Oncology Inc. (“Predictive Oncology”) is a knowledge-driven company focused on applying artificial intelligence (“AI”) to support the development of optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success. The company offers a suite of solutions for oncology drug development from early discovery to clinical trials. The Company operates in three 3D The Company has determined that it will focus its resources on applying AI to support the development of optimal cancer therapies, partnering with biopharma clients to help prioritize drugs for development and identify biomarker-informed indications. Its platform provides a more informed decision tool to select optimal drug/tumor combinations to increase the probability of success during drug development. As a result of this focused approach, the Company has consolidated its brand under the Predictive Oncology name. Going forward, the Company will operate under the Predictive Oncology tradename with laboratory operations in Pittsburgh, Pennsylvania and Birmingham, Alabama. As of January 1, 2023, The Company has three 3D Note 9 Segments. The Company had cash and cash equivalents of $18,597,119 as of March 31, 2023. March 31, 2023, twelve may
Stockholders' Equity, Policy [Policy Text Block]	Recent Developments On April 19, 2023, one twenty April 24, 2023.
Effect of Covid-19 Pandemic [Policy Text Block]	Impact of the Coronavirus Disease 2019 In response Coronavirus Disease 2019 19” 19. 19, may 19 may 19, may 19 10 March 21, 2023.
Basis of Accounting, Policy [Policy Text Block]	Interim Financial Statements The Company has prepared the condensed consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim condensed consolidated financial statements. Accordingly, they do not 10 March 21, 2023. may not
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to the prior year’s condensed consolidated financial statements to conform to the current year presentation. The reclassifications had no
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents The Company considers all highly liquid instruments with maturities when purchased of three
Receivable [Policy Text Block]	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the status of individual accounts. Amounts recorded in accounts receivable on the condensed consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance is maintained to provide for the estimated amount of receivables that will not 30 30 not March 31, 2023 December 31, 2022.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 6 Derivatives
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers, software, and office equipment 3 - 10 Leasehold improvements (1) 2 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3 ( 1 Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term. Upon retirement or sale of property and equipment, the cost and related accumulated depreciation or amortization are removed from the condensed consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Long-lived Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying condensed consolidated balance sheets. The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment may not may not not
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill In accordance with ASC 350, Intangibles Goodwill and Other not December 31, may not To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first not may first 2017 04, Simplifying the Test for Goodwill Impairment 3 1 Note 4 Intangible Assets
Lessee, Leases [Policy Text Block]	Leases At inception of a contract, a determination is made whether an arrangement meets the definition of a lease. A contract contains a lease if there is an identified asset, and the Company has the right to control the asset. Operating leases are recorded as right-of-use (“ROU”) assets with corresponding current and noncurrent operating lease liabilities on our condensed consolidated balance sheets. Financing leases are included within fixed assets with corresponding current within other current liabilities and noncurrent within other long-term liabilities on our condensed consolidated balance sheets. ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 not The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping, and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Eagan reportable segment. Revenue from Clinical Testing Clinic diagnostic testing is comprised of our Tumor Drug Response Testing (“ChemoFx”) and Genomic Profiling (“BioSpeciFx”) tests. The Tumor Drug Response Testing test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression and/or status of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Pittsburgh’s payments terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a patient, it will account for the change as an increase to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts, as defined in ASC 606, Revenue from Contracts with Customers 30 Contract Research Organization ( CRO ) and AI-Driven Business Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. Accounts receivable totaled $282,763 and $331,196 as of March 31, 2023 December 31, 2022, The Company’s contract liabilities related primarily to 3D March 31, 2023 December 31, 2022, Practical Expedients The Company has elected the practical expedient not
Valuation and Accounting for Stock Options and Warrants, Policy [Policy Text Block]	Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term. The fair value of each option grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: For the three months ended March 31, 2023 2022 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 90.8% 86.5% Risk-free interest rate 3.38% - 3.55% 1.83% - 1.92% Expected life (years) 10 10 On January 1, 2023, 815 40 35 815” 815 first 815, not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $38,805 and $68,219 for the three March 31, 2023 2022,
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes 740” 740, There is no income tax provision in the accompanying condensed consolidated statements of net loss due to the cumulative operating losses that indicate a 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not Under Internal Revenue Code Section 382, may not not 382 may Tax years subsequent to 2002
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one March 31, 2023,
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no Recently Adopted Accounting Standards In June 2016, 2016 13, not 2016 13 January 1, 2023; not In August 2020, 2020 06, 2020 06” 2020 06 may 12b 2 1934 , 2020 06 December 15, 2023, 2020 06 January 1, 2023 not

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers, software, and office equipment 3 - 10 Leasehold improvements (1) 2 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	For the three months ended March 31, 2023 2022 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 90.8% 86.5% Risk-free interest rate 3.38% - 3.55% 1.83% - 1.92% Expected life (years) 10 10

Note 2 - Inventories (Tables)

Note 2 - Inventories (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of March 31, 2023 As of December 31, 2022 Finished goods $ 275,654 $ 290,616 Raw materials 97,944 133,183 Work-In-Process 6,694 6,694 Total $ 380,292 $ 430,493

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of March 31, 2023 As of December 31, 2022 Computers, software, and office equipment $ 485,837 $ 463,292 Leasehold improvements 669,067 535,527 Laboratory equipment 3,559,362 3,559,362 Manufacturing tooling 133,285 121,120 Demo equipment 31,555 31,554 Total 4,879,106 4,710,855 Less: Accumulated depreciation (3,107,369 ) (2,877,600 ) Total Property and Equipment, Net $ 1,771,737 $ 1,833,255

Note 4 - Intangible Assets (Tab

Note 4 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of March 31, 2023 As of December 31, 2022 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Impairment Net Carrying Amount Patents & Trademarks $ 534,847 $ (261,878 ) $ 272,969 $ 509,141 $ (255,276 ) $ - $ 253,865 Developed Technology - - - 3,500,000 (386,459 ) (3,113,541 ) - Customer Relationships - - - 200,000 (22,083 ) (177,917 ) - Tradename - - - 80,000 (22,083 ) (57,917 ) - $ 534,847 $ (261,878 ) $ 272,969 $ 4,289,141 $ (685,901 ) $ (3,349,375 ) $ 253,865
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending December 31, Expense Remainder of 2023 $ 20,057 2024 26,743 2025 26,743 2026 26,743 2027 26,743 Thereafter 145,940 Total $ 272,969

Note 5 - Stockholders' Equity_2

Note 5 - Stockholders' Equity, Stock Options and Warrants (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2021 53,144 $ 96.60 1,584,995 $ 33.20 Issued 1,599 8.40 1,053,136 14.00 Forfeited (2,013 ) 17.60 - - Expired (3,677 ) 208.40 (5,422 ) 329.60 Cancelled - - (816,272 ) 30.20 Outstanding at December 31, 2022 49,053 $ 91.69 1,816,437 $ 22.60 Issued 488 6.70 - - Forfeited - - - - Expired (1,736 ) 148.58 (4,058 ) 200.00 Outstanding at March 31, 2023 47,805 $ 84.88 1,812,379 $ 22.20

Note 6 - Derivatives (Tables)

Note 6 - Derivatives (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative liability balance at December 31, 2021 $ 129,480 Gain recognized to revalue derivative instrument at fair value (1,908 ) Derivative liability balance at March 31, 2022 $ 127,572 Derivative liability balance at December 31, 2022 $ 13,833 Gain recognized to revalue derivative instrument at fair value (953 ) Derivative liability balance at March 31, 2023 $ 12,880

Note 7 - Loss Per Share (Tables

Note 7 - Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended 2023 2022 Numerator: Net loss attributable to common stockholders: basic and diluted calculation $ (3,421,802 ) $ (3,370,715 ) Denominator: Weighted average common shares outstanding-basic 3,968,099 3,291,722 Effect of diluted stock options, warrants, and preferred stock (1) - - Weighted average common shares outstanding - diluted 3,968,099 3,291,722 Loss per common share-basic and diluted $ (0.86 ) $ (1.02 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2023 2022 Options 47,805 51,529 Restricted Stock Units 2,500 22,084 Warrants 1,812,379 1,583,063 Series B Convertible Preferred Stock 16 16

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Lease, Cost [Table Text Block]	March 31, 2023 Weighted average remaining lease term – operating leases in years 4.76 Weighted average discount rate – operating leases 12 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Remainder of 2023 $ 566,485 2024 844,933 2025 839,665 2026 803,724 2027 827,909 Thereafter 139,022 Total lease payments 4,021,738 Less: interest (997,215 ) Present value of lease liabilities $ 3,024,523

Note 9 - Segments (Tables)

Note 9 - Segments (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended March 31, 2023 2022 Pittsburgh $ 10,627 $ 21,980 Eagan 215,619 279,270 Birmingham 13,649 12,916 Corporate - 402 Total $ 239,895 $ 314,568 Three Months Ended March 31, 2023 2022 Pittsburgh $ (1,159,105 ) $ (1,314,513 ) Eagan (285,397 ) (48,602 ) Birmingham (482,696 ) (402,828 ) Corporate (1,494,604 ) (1,604,772 ) Total $ (3,421,802 ) $ (3,370,715 ) As of As of March 31, December 31, 2023 2022 Pittsburgh $ 3,746,088 $ 1,055,228 Eagan 1,125,840 946,394 Birmingham 1,441,002 1,353,434 Corporate 18,748,649 22,379,588 Total $ 25,061,579 $ 25,734,644

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual)		3 Months Ended
	Apr. 19, 2023	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Number of Tumor Samples		150,000
Number of Operating Segments		3
Cash and Cash Equivalents, at Carrying Value		$ 18,597,119		$ 22,071,523
Long-term Debt, Total		0
Accounts Receivable, Allowance for Credit Loss, Current		0
Accounts Receivable, after Allowance for Credit Loss		282,763		331,196
Contract with Customer, Liability		639,238		$ 602,073
Research and Development Expense		38,805	$ 68,219
Income Tax Expense (Benefit), Total		0
Unrecognized Tax Benefits, Ending Balance		0
Cash, Uninsured Amount		$ 57,750
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	Mar. 31, 2023
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	2 years	[1]
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Laboratory Equipment [Member]
Property, plant, and equipment, useful life (Year)	4 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	10 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Laboratory Equipment [Member]
Property, plant, and equipment, useful life (Year)	10 years
[1]Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Valuation Assumptions (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Expected dividend yield	0%	0%
Expected life (years) (Year)	10 years	10 years
Minimum [Member]
Risk-free interest rate	3.38%	1.83%
Maximum [Member]
Risk-free interest rate	3.55%	1.92%

Note 2 - Inventories - Schedule

Note 2 - Inventories - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Finished goods	$ 275,654	$ 290,616
Raw materials	97,944	133,183
Work-In-Process	6,694	6,694
Total	$ 380,292	$ 430,493

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Depreciation	$ 231,189	$ 220,078

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Property, Plant, and Equipment Gross	$ 4,879,106	$ 4,710,855
Less: Accumulated depreciation	3,107,369	2,877,600
Total Property and Equipment, Net	1,771,737	1,833,255
Office Equipment [Member]
Property, Plant, and Equipment Gross	485,837	463,292
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	669,067	535,527
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	3,559,362	3,559,362
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	133,285	121,120
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 31,555	$ 31,554

Note 4 - Intangible Assets (Det

Note 4 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Amortization of Intangible Assets	$ 6,665	$ 103,524
Impairment of Intangible Assets (Excluding Goodwill)	$ 0		$ 3,349,375

Note 4 - Intangible Assets - Co

Note 4 - Intangible Assets - Components of Intangible Assets (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accumulated Amortization	$ (261,878)	$ (685,901)
Net Carrying Amount	272,969
Total, Gross Carrying Costs	534,847	4,289,141
Total, Net Carrying Amount	272,969	253,865
Impairment	0	(3,349,375)
Trade Names 1 [Member]
Tradename	0	80,000
Tradename	0	(22,083)
Tradename	0	0
Impairment, indefinite		(57,917)
Patents and Trademarks [Member]
Gross Carrying Costs	534,847	509,141
Accumulated Amortization	(261,878)	(255,276)
Net Carrying Amount	272,969	253,865
Impairment, finite		0
Developed Technology Rights [Member]
Gross Carrying Costs	0	3,500,000
Accumulated Amortization	0	(386,459)
Net Carrying Amount	0	0
Impairment, finite		(3,113,541)
Customer Relationships [Member]
Gross Carrying Costs	0	200,000
Accumulated Amortization	0	(22,083)
Net Carrying Amount	$ 0	0
Impairment, finite		$ (177,917)

Note 4 - Intangible Assets - Es

Note 4 - Intangible Assets - Estimated Future Amortization Expense (Details)	Mar. 31, 2023 USD ($)
Remainder of 2023	$ 20,057
2024	26,743
2025	26,743
2026	26,743
2027	26,743
Thereafter	145,940
Total	$ 272,969

Note 5 - Stockholders' Equity_3

Note 5 - Stockholders' Equity, Stock Options and Warrants (Details Textual) - USD ($)		3 Months Ended
	Mar. 16, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Preferred Stock, Shares Authorized (in shares)		20,000,000		20,000,000
Share-Based Payment Arrangement, Expense		$ 9,287	$ 36,518
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 5,584
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Month)		21 months
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		3 years
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		3 years
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		10 years
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 19,971
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Month)		10 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares)		2,500
Series F Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)	80,000	80,000		0
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01	$ 0.01		$ 0.01
Preferred Stock Dividends, Shares Per Share (in shares)	0.001
Preferred Stock, Shares Issued (in shares)	79,404	79,404
Preferred Stock, Voting Rights Per Share (in dollars per share)	$ 1,000,000
Dividends Payable, Date of Record	Mar. 27, 2023

Note 5 - Stockholders' Equity_4

Note 5 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Warrants, outstanding (in shares)	1,816,437	1,584,995
Warrants, average exercise price (in dollars per share)	$ 22.60	$ 33.20
Warrants, issued (in shares)	0	1,053,136
Issued, average exercise price, warrants (in dollars per share)	$ 0	$ 14
Warrants,forfeited (in shares)	0	0
Warrants,expired (in shares)	(4,058)	(5,422)
Expired, average exercise price, warrants (in dollars per share)	$ 200	$ 329.60
Warrants,cancelled (in shares)		(816,272)
Cancelled, average exercise price, warrants (in dollars per share)		$ 30.20
Warrants, outstanding (in shares)	1,812,379	1,816,437
Warrants, average exercise price, warrants (in dollars per share)	$ 22.20	$ 22.60
Share-Based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	49,053	53,144
Average Exercise Price Outstanding (in dollars per share)	$ 91.69	$ 96.60
Number of Shares Issued (in shares)	488	1,599
Average Exercise Price Issued (in dollars per share)	$ 6.70	$ 8.40
Number of Shares Forfeited (in shares)	0	(2,013)
Average Exercise Price Forfeited (in dollars per share)	$ 0	$ 17.60
Number of Shares Expired (in shares)	(1,736)	(3,677)
Average Exercise Price Expired (in dollars per share)	$ 148.58	$ 208.40
Number of Shares Cancelled (in shares)		0
Average Exercise Price Cancelled (in dollars per share)		$ 0
Number of Shares Outstanding (in shares)	47,805	49,053
Average Exercise Price Outstanding (in dollars per share)	$ 84.88	$ 91.69

Note 6 - Derivatives (Details T

Note 6 - Derivatives (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
A, B and Agent Warrants [Member]
Derivative Liability	$ 2,936		$ 3,355
Derivative, Gain (Loss) on Derivative, Net	419	$ 1,190
Agent Warrants Issued in Connection with May 2020 Offering [Member]
Derivative Liability	4,144		4,479
Derivative, Gain (Loss) on Derivative, Net	335	505
Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability	5,800		$ 5,999
Derivative, Gain (Loss) on Derivative, Net	$ 199	$ 213

Note 6 - Derivatives - Change i

Note 6 - Derivatives - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Derivative liability balance	$ 13,833	$ 129,480
Gain recognized to revalue derivative instrument at fair value	(953)	(1,908)
Derivative liability balance	$ 12,880	$ 127,572

Note 7 - Loss Per Share (Detail

Note 7 - Loss Per Share (Details Textual) - Series B Convertible Preferred Stock [Member] - shares	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Preferred Stock, Shares Outstanding (in shares)	79,246	79,246	79,246
Preferred Stock, Convertible, Shares Issuable (in shares)	16		16

Note 7 - Loss Per Share - Share

Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Net loss attributable to common stockholders: basic and diluted calculation		$ (3,421,802)	$ (3,370,715)
Weighted average shares used in computation - basic and diluted (in shares)	[1]	3,968,099	3,291,722
Effect of diluted stock options, warrants, and preferred stock (1) (in shares)		0	0
Weighted average common shares outstanding - diluted (in shares)		3,968,099	3,291,722
Net loss per common share - basic and diluted (in dollars per share)		$ (0.86)	$ (1.02)
[1]The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Three Months Ended March 31, 2023 2022 Options 47,805 51,529 Restricted Stock Units 2,500 22,084 Warrants 1,812,379 1,583,063 Series B Convertible Preferred Stock 16 16

Note 7 - Loss Per Share - Antid

Note 7 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	47,805	51,529
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities (in shares)	2,500	22,084
Warrant [Member]
Antidilutive Securities (in shares)	1,812,379	1,583,063
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	16	16

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	3 Months Ended
	Mar. 31, 2023 USD ($) ft² a	Mar. 31, 2022 USD ($)	Jan. 04, 2023 USD ($) ft² a	Dec. 31, 2022 USD ($)
Operating Lease, Right-of-Use Asset | $	$ 3,062,598		$ 2,922,365	$ 211,893
Operating Lease, Expense | $	214,015	$ 179,788
Operating Lease, Liability | $	$ 3,024,523
Corporate Office, Minnesota [Member]
Area of Real Estate Property (Square Foot)	5,773
Corporate Office, Minnesota, Used for Office Space [Member]
Area of Real Estate Property (Square Foot)	2,945
Corporate Office, Minnesota, Used for Manufacturing [Member]
Area of Real Estate Property (Square Foot)	2,828
Helomics' Offices [Member]
Area of Real Estate Property (Square Foot) | a			20,835
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract (Year)			5 years
Helomics Offices, Lease Area for Office Space [Member]
Area of Real Estate Property (Square Foot) | a			4,418
Helomics Offices, Lease Area for Laboratory [Member]
Area of Real Estate Property (Square Foot)			16,417
Soluble Biodtech Offices in Birmingham, Alabama [Member]
Area of Real Estate Property (Square Foot) | a	5,274

Note 8 - Leases - Lease Informa

Note 8 - Leases - Lease Information (Details)	Mar. 31, 2023
Weighted average remaining lease term – operating leases in years (Year)	4 years 9 months 3 days
Weighted average discount rate – operating leases	12%

Note 8 - Leases - Rent Obligati

Note 8 - Leases - Rent Obligation (Details)	Mar. 31, 2023 USD ($)
Remainder of 2023, operating lease	$ 566,485
2024, operating lease	844,933
2025, operating lease	839,665
2026, operating lease	803,724
2027, operating lease	827,909
Thereafter, operating lease	139,022
Total lease payments	4,021,738
Less: interest	(997,215)
Present value of lease liabilities	$ 3,024,523

Note 9 - Segments (Details Text

Note 9 - Segments (Details Textual)	3 Months Ended
	Mar. 31, 2023
Number of Operating Segments	3
Number of Tumor Samples	150,000

Note 9 - Segments - Segments (D

Note 9 - Segments - Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Revenue	$ 239,895	$ 314,568
Net loss	(3,421,802)	(3,370,715)
Assets	25,061,579	25,734,644	$ 25,734,644
Operating Segments [Member] | Pittsburgh [Member]
Revenue	10,627	21,980
Net loss	(1,159,105)	(1,314,513)
Assets	3,746,088	1,055,228
Operating Segments [Member] | Eagan [Member]
Revenue	215,619	279,270
Net loss	(285,397)	(48,602)
Assets	1,125,840	946,394
Operating Segments [Member] | Birmingham [Member]
Revenue	13,649	12,916
Net loss	(482,696)	(402,828)
Assets	1,441,002	1,353,434
Corporate, Non-Segment [Member]
Revenue	0	402
Net loss	(1,494,604)	(1,604,772)
Assets	$ 18,748,649	$ 22,379,588

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual)	Apr. 19, 2023 shares	May 05, 2023 $ / shares	Mar. 31, 2023 shares	Mar. 16, 2023 shares	Dec. 31, 2022 shares
Common Stock, Shares Authorized (in shares)			200,000,000		200,000,000
Series F Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)			79,404	79,404
Preferred Stock, Shares Outstanding (in shares)			79,404		0
Subsequent Event [Member]
Common Stock, Shares Authorized (in shares)	200,000,000
Subsequent Event [Member] | Common Stock [Member]
Sale of Stock, Price Per Share (in dollars per share) | $ / shares		$ 1
Subsequent Event [Member] | Series F Preferred Stock [Member]
Preferred Stock, Shares Outstanding (in shares)	0
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20
Reverse Stock Split [Member] | Subsequent Event [Member] | Minimum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	2
Reverse Stock Split [Member] | Subsequent Event [Member] | Maximum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	25